SRPT241122C119000
- 2.13
- 0.000.00%
Sarepta Therapeutics Newsroom
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $197
Express News | Sarepta Therapeutics Inc : JP Morgan Cuts Target Price to $197 From $202
S&P 500 Futures Climb In Premarket Trading; Target, Fabrinet Lag
Barclays Initiates Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $209
High Alpha Stocks That Are Rated 'Overweight' – MS
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $210
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Buy Rating on Sarepta Therapeutics: Confidence in Elevidys' Market Potential and Strategic Expansion
Statutory Earnings May Not Be The Best Way To Understand Sarepta Therapeutics' (NASDAQ:SRPT) True Position
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem
Sarepta's Valuation Seen As An Easy Pill to Swallow -- Market Talk
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and DocGo (DCGO)
Notable Analyst Calls This Week: Carvana, Devon Energy and Palantir Among Top Picks
Barclays Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $209
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $150 to $209
Sarepta Therapeutics: Strong Elevidys Sales Drive Buy Rating Amid Portfolio Optimism and Favorable Valuation